Pancreatic cancer, treatment options, and GI-4000

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 4, 2015, Pages 931-937

  Hartley, Marion L ^a   Bade, Najeebah A ^a   Prins, Petra A ^a   Ampie, Leonel ^a   Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

GI 4000; Immunotherapy; KRAS; Pancreatic cancer; Vaccine

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; FLUOROURACIL; GEMCITABINE; GI 4000 VACCINE; INTERLEUKIN 2; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); ANALOGS AND DERIVATIVES; GENETICS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS;

EID: 84945179119     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1011017     Document Type: Article

References (63)

1. American Cancer Society. American Cancer Society. Cancer Facts & Figures 2014. Atlanta; 2014.
2. Cameron JL, Riall TS, Coleman J, Belcher K A. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244(1):10-5; PMID:16794383; http://dx. doi. org/10. 1097/01. sla. 0000217673. 04165. ea
3. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68-72; discussion 72-73; PMID:8380315; http://dx. doi. org/10. 1016/S0002- 9610(05)80406-4
4. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237(1):74-85; PMID:12496533; http://dx. doi. org/10. 1097/01. SLA. 0000041266. 10047. 38
5. Liao WC, Chien KL, Lin YL, Lin JT, Wang HP, Tu YK. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14:1095-103; PMID:24035532; http://dx. doi. org/10. 1016/S1470- 2045(13)70388-7
6. Yu Z, Zhong W, Tan ZM, Wang LY, Yuan YH. Gemcitabine adjuvant therapy for resected pancreatic cancer: a meta-analysis. Am J Clin Oncol 2013; Aug 7 (Epub ahead of print); http://dx. doi. org/10. 1097/ COC. 0b013e3182a46782
7. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol 2003; 21(18):3409-14; PMID:12972517; http://dx. doi. org/10. 1200/JCO. 2003. 03. 007
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2007; 25:1960-66; PMID:17452677; http://dx. doi. org/ 10. 1200/JCO. 2006. 07. 9525
9. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou- Bourgade S, de la Fouchardière C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19):1817-25; http://dx. doi. org/10. 1056/NEJMoa1011923
10. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369(18):1691-703; PMID:24131140; http://dx. doi. org/10. 1056/NEJMoa1304369
11. Goldstein D, Hassan R, Maraghi El, RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J et al. Updated survival from a randomized phase III trial (MPACT) of nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2014; 32(3): Abstract 178.
12. Von Hoff DD, Goldstein D, Renschler MF. Albuminbound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med 2014; 370(5):479-80; PMID:24476438; http://dx. doi. org/10. 1056/ NEJMc1314761
13. American Society of Clinical Oncology (ASCO). FDA approves Abraxane plus gemcitabine for metastatic pan creatic cancer. Available at: http://www. asco. org/advo cacy/fda-approves-abraxane-plus-gemcitabine-meta static-pancreatic-cancer
14. Hauschild A, Volkenandt M. [Adjuvant therapy of malignant melanoma]. Ther Umsch 1999; 56(6):324-9. Available at: http://www. mrw. interscience. wiley. com/cochrane/clcentral/articles/636/CN-00165636/ frame. html; http://dx. doi. org/10. 1024/0040- 5930. 56. 6. 324
15. Hauschild A. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol 2009; 16(3):3-6. Available at: http://www. pubmedcentral. nih. gov/articlerender. fcgi?artid=2695706&tool=pmcentrez&rendertype=ab stract; PMID:19526078; http://dx. doi. org/10. 3747/ co. v16i3. 447
16. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers- Freezer L, Morton KE, White DE, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal Cancer. J Clin Oncol 2003; 21(16):3127-32; http://dx. doi. org/10. 1056/ NEJMc1314761; 10. 1200/JCO. 2003. 02. 122
17. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia- CEA vaccine. J Natl Cancer Inst 1995; 87:982- 90; PMID:7629885; http://dx. doi. org/10. 1093/jnci/ 87. 13. 982
18. Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999; 17(1):332-7.
19. Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL MR. Phase I trial of a recombinant yeast- CEA vaccine (GI-6207) in adults with metastatic CEAexpressing carcinoma. Cancer Immunol Immunother. 2014; 63(3):225-34; PMID:24327292; http://dx. doi. org/10. 1007/s00262-013-1505-8
20. Nordqvist C. Therion reports results of phase 3 PANVAC- VF trial and announces plans for company sale [press release]. PR Newswire. http://www. lifesciences world. com/news/view/7586. Published 2006
21. Rahma OE, Khleif SN. Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol 2011; 7 (8):517-64.
22. Azijli K, Stelloo E, Peters GJ, VAN DEN Eertwegh AJM. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res 2014; 34(4):1493-505. Available at: http://www. ncbi. nlm. nih. gov/pubmed/ 24692676; PMID:24692676
23. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel T, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. ASCO Meet Abstr Jun 11, 2014:5009 Available at: http://meeting. ascopubs. org/cgi/content/abstract/32/15_suppl/5009
24. Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Knox JJ, Pal SK, Voss MH, Sharma P et al. Nivolumab (anti-PD-1; BMS-936558, ONO- 4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meet Abstr 2014; 32 (15 suppl):5010. Available at: http://meeting. ascopubs. org/ cgi/content/abstract/32/15_suppl/5010
25. Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Razak ARA, Pal SK, Voss MH, Sharma P et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meet Abstr 2014; 32 (15 suppl):4504. Available at: http://meeting. ascopubs. org/ cgi/content/abstract/32/15_suppl/4504
26. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci 2014; 39(2):91-100; PMID:24388967; http://dx. doi. org/10. 1016/j. tibs. 2013. 12. 004
27. Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A 2013; 110(51):20723-8; PMID:24297898; http://dx. doi. org/10. 1073/pnas. 1314307110
28. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 2014; 111:817-22; http://dx. doi. org/10. 1038/ bjc. 2014. 215
29. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res 2012; 5(1):19-27. Available at: http://www. ncbi. nlm. nih. gov/pubmed/24603996; PMID:22574233
30. Goodsell DS. The molecular perspective: the ras oncogene. Oncologist 1999; 4(3):263-4; PMID:10394594
31. Alberts SR. K-ras inhibitors and pancreatic cancer. M. D. Anderson Solid Tumor Oncol Ser 2008:601-7 http://link. springer. com/chapter/10. 1007%2F978-0- 387-69252-4_35
32. Wang JY, Wang YH, Jao SW, Lu CY, Kuo CH, Hu HM, Hsieh JS, Chong IW, Cheng TL, Lin SR. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep 2006; 16:1245-52; PMID:17089045
33. Slebos RJC, Hoppin JA, Tolbert PE, Holly EA, Brock JW, Zhang RH, Bracci PM, Foley J, Stockton P, McGregor LM, et al. K-ras and p53 in Pancreatic Cancer: Association with Medical History, Histopathology, and Environmental Exposures in a Population-based Study. 2000; 9 11:1223-32
34. Coeshott C, Holmes T, Mattson A, Bellgrau D, King T, Guo Z, Roder H, Roder J, Cohn A, Rodell TC. Immune Responses To Mutated Ras - Development Of A Yeast Based Immunotherapeutic. In: AACR-RAS Oncogene Conference 2014.
35. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57:1731-4; PMID:9135016
36. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2(12):897-909; PMID:12459728; http://dx. doi. org/10. 1038/nrc949
37. Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. 2012; 122(2):639-53; PMID:22232209; http:// dx. doi. org/10. 1172/JCI59227DS1
38. Di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144(6):1220-9; PMID:23622131; http://dx. doi. org/10. 1053/j. gastro. 2013. 01. 071
39. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, et al. Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149(3):656-70; PMID:22541435; http:// dx. doi. org/10. 1016/j. cell. 2012. 01. 058
40. Berndt N, Hamilton AD, Sebti SM, Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011; 11:775-91; PMID:22020205.
41. Richards DA, Muscarella P, Bekaii-Saab T, Wilfong LS, Velanovich V, Raynov J, Flynn PJ, Fisher WE, Whiting SH, Timcheva C, et al. A proteomic signature predicts response to a therapeutic vaccine in pancreas cancer; analysis from the GI-4000-02 trial. In: AACR Annual Meeting 2014, Abstract # 5314.
42. Fruci D, Lo Monaco E, Cifaldi L, Locatelli F, Tremante E, Benevolo M, Giacomini P. T and NK cells: two sides of tumor immunoevasion. J Transl Med 2013; 11:30. Available at: http://www. pubmedcentral. nih. gov/articlerender. fcgi?artid=3621684&tool=pmcen trez&rendertype=abstract; PMID:23379575; http://dx. doi. org/10. 1186/1479-5876-11-30
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-74; PMID:21376230; http://dx. doi. org/10. 1016/j. cell. 2011. 02. 013
44. Yang L, Pang Y, Moses HL. TGF-Beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31(6):220-7; PMID:20538542; http://dx. doi. org/ 10. 1016/j. it. 2010. 04. 002
45. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182(8):4499-506; PMID:19342621; http:// dx. doi. org/10. 4049/jimmunol. 0802740
46. Chatterjee B, Smed-Sörensen A, Cohn L, Chalouni C, Vandlen R, Lee BC, Widger J, Keler T, Delamarre L, Mellman I. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 2012; 120(10):2011-20; PMID:22791285; http://dx. doi. org/10. 1182/blood-2012-01-402370
47. Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009; 10(12):1237-44. Available at: http://www. nature. com. proxy. library. georgetown. edu/ ni/journal/v10/n12/full/ni. 1822. html. Accessed May 2, 2014; PMID:19915624; http://dx. doi. org/10. 1038/ ni. 1822
48. Fehres CM, UngerWWJ, Garcia-Vallejo JJ, van Kooyk Y. Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol 2014; 5:149. Available at: http://www. fron tiersin. org/Journal/10. 3389/fimmu. 2014. 00149/ abstract. Accessed May 1, 2014; PMID:24782858; http://dx. doi. org/10. 3389/fimmu. 2014. 00149
49. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67(19):9518-27; PMID:17909062; http://dx. doi. org/10. 1158/0008-5472. CAN-07-0175
50. Collins MA, Pasca di Magliano M. Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol 2013; 4(January):407; PMID:24478710; http://dx. doi. org/10. 3389/fphys. 2013. 00407
51. Vonderheide RH, Bayne LJ. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 2013; 25(2):200-5; PMID:23422836; http://dx. doi. org/10. 1016/j. coi. 2013. 01. 006
52. Steele CW, Jamieson NB, Evans TR, McKay CJ, Sansom OJ, Morton JP, Carter CR. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer 2013; 108(5):997-1003; PMID:23385734; http://dx. doi. org/10. 1038/bjc. 2013. 24
53. Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer J 2012; 18(6):642-52. Available at: http://www. pubmedcentral. nih. gov/articleren der. fcgi?artid=3539747&tool=pmcentrez&renderty pe=abstract; PMID:23187853; http://dx. doi. org/ 10. 1097/PPO. 0b013e3182756903
54. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53(4):549-54; PMID:2453289; http://dx. doi. org/10. 1016/0092-8674(88)90571-5
55. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988; 16(16):7773-82; http://dx. doi. org/10. 1093/ nar/16. 22. 10952
56. Niccolai E, Prisco D, D'Elios MM, Amedei A. What is recent in pancreatic cancer immunotherapy? Biomed Res Int 2013; 2013:492372; PMID:23509731
57. Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma K, et al. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol 2011; 2011:267539; PMID:21922022
58. Shahda S, O'Neil B. GI-4000 in KRAS mutant cancers. Expert Opin Investig Drugs 2014; 23(2):273-8. Available at: http://informahealthcare. com/doi/abs/ 10. 1517/13543784. 2014. 876408. Accessed May 5, 2014
59. Sam HW, Muscarella P, Rosenmurgy E, Fisher WE, Richards DA, Harrell F Jr., Ferraro J, Speyer S, Cohn A. A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations. J Clin Oncol 2010; 28 15s (suppl; abstr TPS226). Available at: http:// meetinglibrary. asco. org/content/42584-74 (accompanying poster).
60. Globoimmune. GlobeImmune power point presentation: recombinant DNA advisory committee - GI-6301. Available at: http://osp. od. nih. gov/sites/default/ files/1_1107_1119_Gulley. pdf
61. Cohn A, Morse MA, O'Neil B, Bellgrau D, Duke RC, Franzusoff AJ, Munson S, Ferraro J, Rodell TC. Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: preliminary safety and immunogenicity results from a phase 1 trial. J Clin Oncol 2005; 23(16 Suppl):2571
62. Chaft JE, Litvak A, Arcila ME, Patel P, D'Angelo SP, Krug LM, Rusch V, Mattson A, Coeshott C, Park B, et al. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer 2014; 15 6:405-10. PMID:25044103; http://dx. doi. org/10. 1016/j. cllc. 2014. 06. 002
63. GlobeImmune, Inc. GlobeImmune Announces Presentation of GI-4000 Phase 2 Data at IASLC World Conference on Lung Cancer, GlobeNewswire Europe, October 27, 2013 4:02 PM (Sydney, Australia, October 28, 2013).